Search

Displaying results 831 - 840 of 10000 in total
  1. Drug

    Abiraterone

    go.drugbank.com/drugs/DB05812
    ApprovedInvestigational

    Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis … [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively.

  2. Drug

    Sodium oxybate

    go.drugbank.com/drugs/DB09072
    ApprovedInvestigational

    in May 2023. … [L46302] In some countries, sodium oxybate has been investigated and used in alcohol withdrawal syndrome (AWS) to aid abstinence maintenance in alcohol use disorders.[A251440, A251445]

  3. Drug

    Hexaminolevulinate

    go.drugbank.com/drugs/DB06261
    ApprovedInvestigational

    In Europe, Hexaminolevulinate is marketed under the brand Hexvix®. … On May 28, 2010, the U.S.

  4. Target

    ATP synthase F(1) complex subunit beta, mitochondrial

    go.drugbank.com/bio_entities/BE0003841
    TargetEnzymeHumans

    ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). … Catalytic subunit beta, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which

    Polypeptides: ATP synthase F(1) complex subunit beta, mitochondrial
  5. Target

    Actin-related protein 2/3 complex subunit 2

    go.drugbank.com/bio_entities/BE0004252
    TargetHumans

    Actin-binding component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:9230079). … The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:9230079).

    Polypeptides: Actin-related protein 2/3 complex subunit 2Synonyms: Arp2/3 complex 34 kDa subunit
  6. Target

    Actin-related protein 2/3 complex subunit 4

    go.drugbank.com/bio_entities/BE0004254
    TargetHumans

    Actin-binding component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:9230079). … The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:9230079).

    Polypeptides: Actin-related protein 2/3 complex subunit 4Synonyms: Arp2/3 complex 20 kDa subunit
  7. Target

    Actin-related protein 2/3 complex subunit 5

    go.drugbank.com/bio_entities/BE0004255
    TargetHumans

    Component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:9230079). … The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:9230079).

    Polypeptides: Actin-related protein 2/3 complex subunit 5Synonyms: Arp2/3 complex 16 kDa subunit
  8. Drug

    Ambrisentan

    go.drugbank.com/drugs/DB06403
    ApprovedInvestigational

    It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. … In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability.

  9. Drug

    Propanoic acid

    go.drugbank.com/drugs/DB03766
    ApprovedInvestigationalVet approvedWithdrawn

    Its use as a food additive is also approved in Europe. Sodium propionate is is prepared by neutralizing propionic acid with sodium hydroxide. … Sodium propionate was previously approved in Canada as an active ingredient in Amino-Cerv (used to treat inflammation or injury of the cervix).

  10. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    US in December 2021. … Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the